IONS
Ionis Pharmaceuticals Inc
$54.73
-0.20 (-0.36%)
At close · Jul 15
Market Cap
$9.04B
Shares
165,262,556
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$943.71M
+33.8%
FY2025
Net Income
-$381.39M
+16%
FY2025
Gross Margin
98.31%
-0.1pp
FY2025
Operating Margin
-40.45%
+26.9pp
FY2025
Diluted EPS
-$2.38
+21.7%
FY2025
Operating Cash Flow
-$268.58M
+46.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $875M – $900M | $1.06B | $943.71M | $705.14M | $787.65M | $587.37M | $810.46M | $729.26M | $1.12B | $599.67M | $507.67M | $346.62M | $283.7M | $214.16M | $147.29M | $102.05M | $99.09M | $108.47M | |
| — | $17.43M | $15.91M | $11.22M | $9.13M | $14.12M | $10.84M | $11.95M | $4.38M | $1.82M | — | — | — | — | — | — | — | — | |
| — | $1.04B | $927.8M | $693.92M | $778.51M | $573.25M | $799.61M | $717.32M | $1.12B | $597.85M | — | — | — | — | — | — | — | — | |
| — | — | 98.31% | 98.41% | 98.84% | 97.6% | 98.66% | 98.36% | 99.61% | 99.7% | — | — | — | — | — | — | — | — | |
| — | — | $915.62M | — | — | — | $638.2M | $531M | $461.5M | $411.9M | $372.5M | $340.4M | $319.5M | $238.9M | $173.7M | $158.46M | $157.4M | $145.16M | |
| — | — | — | — | — | — | — | — | — | — | — | $48.62M | $37.17M | $20.14M | $14.92M | $12.52M | $12.79M | $11.67M | |
| — | $467.98M | $393.87M | $267.47M | $232.62M | $150.3M | $186.35M | $354.32M | $286.64M | $244.62M | $108.49M | — | — | — | — | — | — | — | |
| — | — | $2.44M | $2.34M | $2.56M | $2.42M | $2.35M | $2.06M | $1.91M | $1.82M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $661.05M | $483.13M | $392.94M | $359.47M | $261.89M | $198.95M | $170.97M | $170.19M | $156.83M | |
| — | $1.41B | $1.33B | $1.18B | $1.14B | $997.56M | $840.64M | $901.35M | $756.72M | — | — | — | — | — | — | — | — | — | |
| — | -$352.25M | -$381.68M | -$475.08M | -$353.73M | -$410.19M | -$30.19M | -$172.08M | $365.88M | -$61.37M | $24.53M | -$46.32M | -$75.76M | -$47.73M | -$51.67M | -$68.92M | -$71.1M | -$48.36M | |
| — | — | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% | -23.6% | 32.59% | -10.23% | 4.83% | -13.36% | -26.7% | -22.29% | -35.08% | -67.54% | -71.76% | -44.58% | |
| — | $18.31M | $17.26M | $16.99M | $12.66M | $8.12M | $9.35M | $44.99M | $48.77M | $44.79M | $44.75M | $38.8M | $36.73M | $22.21M | $19.36M | $21.15M | $16.73M | $13.23M | |
| — | -$16.28M | -$15.36M | $1.34M | $14.26M | -$7.27M | -$1.13M | -$62K | -$686K | -$182K | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | -$1.41M | -$1.41M | -$3.55M | -$2.23M | |
| — | $34.97M | $10.22M | -$2.89M | -$1.91M | -$7.33M | $10.1M | $16.54M | — | — | — | — | — | $1.26M | $2.38M | $1.47M | $4.18M | -$713K | |
| — | -$325.09M | -$379.6M | -$460.07M | -$333.97M | -$257.99M | -$29.15M | -$170.03M | $346.77M | -$76.16M | -$23.28M | -$83.62M | -$87.91M | -$54.39M | -$66.56M | -$74.59M | -$84.79M | — | |
| — | $1.89M | $1.79M | -$6.17M | $32.32M | $11.74M | -$551K | $316.73M | $43.51M | -$291.14M | -$5.98M | $2.93M | $372K | -$15.41M | — | — | $11K | $92K | |
| — | -$326.98M | -$381.39M | -$453.9M | -$366.29M | -$269.72M | -$28.6M | -$451.29M | $294.15M | $273.74M | -$5.97M | -$86.56M | -$88.28M | -$38.98M | -$60.64M | -$65.48M | -$84.8M | -$61.25M | |
| — | — | -40.41% | -64.37% | -46.5% | -45.92% | -3.53% | -61.88% | 26.2% | 45.65% | -1.18% | -24.97% | -31.12% | -18.2% | -41.17% | -64.16% | -85.58% | -56.47% | |
| — | — | — | — | — | $0 | $0 | -$35.48M | $9.12M | -$58.76M | -$11.33M | — | — | — | — | — | -$4.39M | -$4.39M | |
| — | — | — | — | — | -$444.46M | -$444.46M | -$451.49M | $296.56M | $276.87M | $9.66M | $25.87M | $35.65M | -$38.98M | -$60.64M | -$65.48M | -$84.8M | — | |
| — | -$329.05M | -$375.86M | -$452.06M | -$341.45M | -$294.53M | -$40.19M | -$447.07M | $300.87M | $273.51M | -$7.28M | -$103.35M | -$141.59M | -$20.32M | -$52.04M | -$52.23M | — | — | |
| USD/shares | — | — | -$2.38 | -$3.04 | -$2.56 | -$1.90 | -$0.20 | -$3.23 | $2.12 | $2.09 | $0.08 | $0.21 | -$0.59 | $0.26 | — | — | -$0.85 | -$0.62 |
| USD/shares | — | — | -$2.38 | -$3.04 | -$2.56 | -$1.90 | -$0.20 | -$3.23 | $2.08 | $2.07 | $0.08 | $0.21 | -$0.59 | $0.25 | — | -$0.03 | -$0.85 | -$0.62 |
| shares | — | — | 160.01M | 149.51M | 143.19M | 141.85M | 141.02M | 139.61M | 140M | 132.32M | 124.02M | 120.93M | 119.72M | 117.69M | 110.5M | 100.58M | 99.66M | 99.14M |
| shares | — | — | 160.01M | 149.51M | 143.19M | 141.85M | 141.02M | 139.61M | 142.87M | 134.06M | 126.1M | 120.93M | 119.72M | 117.69M | 110.5M | 100.58M | 99.66M | 99.14M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2022: $124.94M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 25.59×
P/E (TTM)
—
Biotechnology median 7.55×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|
| Ionis Operations | $943,711,000 | $705,138,000 | $787,647,000 | $587,367,000 | — | — | — | — |
| Akcea Therapeutics | — | — | — | — | $152,320,000 | $488,543,000 | $64,867,000 | $43,401,000 |
| Ionis Core | — | — | — | — | $622,941,000 | $858,646,000 | $641,944,000 | $525,185,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research and Development Revenue | $507,863,000 | $412,062,000 | $479,056,000 | $284,009,000 | $468,061,000 | $364,565,000 | — | — |
| Collaborative Agreement Revenue | $465,785,000 | $332,647,000 | $352,657,000 | $207,222,000 | $468,061,000 | $364,565,000 | — | — |
| Commercial | $435,848,000 | $293,076,000 | $308,591,000 | $303,358,000 | $342,395,000 | $364,699,000 | $352,450,000 | $254,922,000 |
| Royalty | $285,529,000 | $257,307,000 | $272,803,000 | — | — | — | — | — |
| Spinraza Royalties | $212,280,000 | $216,090,000 | $240,379,000 | $242,314,000 | $267,776,000 | $286,583,000 | $292,992,000 | $237,930,000 |
| Product | $115,315,000 | $0 | $0 | $30,051,000 | $55,500,000 | $69,999,000 | $42,253,000 | $2,237,000 |
| Tryngolza Sales | $107,526,000 | $0 | $0 | — | — | — | — | — |
| Wainus Royalties | $49,090,000 | $20,207,000 | $0 | $0 | — | — | — | — |
| Wainua Joint Development Revenue | $42,078,000 | $79,415,000 | $126,399,000 | $76,787,000 | $0 | — | — | — |
| Other Commercial | $35,004,000 | $35,769,000 | $35,788,000 | $61,044,000 | $74,619,000 | — | — | — |
| Other Royalties | $24,159,000 | $21,010,000 | $32,424,000 | — | — | — | — | — |
| Dawnzera Sales | $7,789,000 | $0 | $0 | — | — | — | — | — |
| Eplontersen Joint Development Revenue | — | — | — | $76,787,000 | $0 | $0 | — | — |
| Licensing and Other Royalties | — | — | $33,299,000 | $30,993,000 | $19,119,000 | $8,117,000 | $17,205,000 | $14,755,000 |
| Other | — | $22,590,000 | $33,299,000 | $30,993,000 | — | — | — | — |
| Research And Development Revenue Under Collaborative Agreements | — | — | — | — | $468,061,000 | $364,565,000 | $770,149,000 | $344,752,000 |
| SPINRAZA Royalties | — | — | — | — | — | — | $292,992,000 | $237,930,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|
| Ionis Core | $59,294,000 | $335,439,000 | $261,732,000 | $151,397,000 |
| Akcea Therapeutics | -$237,255,000 | $38,074,000 | -$230,816,000 | -$120,470,000 |
Operating Margin by Segment (%)
| Component | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|
| Akcea Therapeutics | -155.8% | 7.8% | -355.8% | -277.6% |
| Ionis Core | 9.5% | 39.1% | 40.8% | 28.8% |
Key facts
CIK
874015
CUSIP
462222100
13F (30d)
59 filings
39 filers
Visit website
Investor relations